Eli Lilly and Company (LLY) Stock Analysis
Is LLY a good investment?
Eli Lilly and Company (LLY) has a Plutrex AI rating of 88.5/100 as of May 26, 2026, indicating a Strong Buy consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Exceptional profitability with ROE of 101.3% and gross margins of 83.0% demonstrating superior operational efficiency and pricing power. Main concern: Elevated leverage with debt-to-equity ratio of 1.58 (24% above industry average) creating moderate financial risk.
Investment Summary
LLY represents an exceptional pharmaceutical growth story with best-in-class fundamentals that dominate this investment decision. ROE of 101.3% (vs industry ~20%) demonstrates extraordinary capital efficiency, while gross margins of 83.0% (vs industry 70%) show superior pricing power. Forward EPS growth of 22.4% next year and 26.6% over 5 years significantly outpaces industry averages of 15.2% and 8.1%. Most compelling is the PEG ratio of 0.79, indicating clear undervaluation despite PE of 39.1x. Recent news around obesity drug Foundayo's early prescription volumes (~4,000 in second week) and strategic acquisitions (Kelonia for $3.25B, Ajax for $2.3B) reinforce the growth trajectory. The analyst consensus target of $1,241.41 represents 40% upside from current $883.96.
Key Strengths
- Exceptional profitability with ROE of 101.3% and gross margins of 83.0% demonstrating superior operational efficiency and pricing power
- Outstanding growth profile with forward EPS growth of 22.4% next year and 26.6% over 5 years, significantly above industry averages
- Attractive valuation with PEG ratio of 0.79 indicating undervaluation despite premium metrics, supported by analyst target of $1,241.41 (40% upside)
Key Concerns
- Elevated leverage with debt-to-equity ratio of 1.58 (24% above industry average) creating moderate financial risk
- Premium valuation metrics (PE 39.1x, P/B 31.5x) require sustained execution of growth projections to justify current levels
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
LLY exhibits exceptional financial metrics across all categories. Profitability is outstanding with ROE of 101.3% (industry ~20%), gross margin of 83.0% (vs 70% industry), operating margin of 44.9% (vs 28.2% industry), and net margin of 31.7% (vs 19.3% industry). Growth prospects are superior with forward EPS growth of 22.4% next year (vs 15.2% industry) and 26.6% over 5 years (vs 8.1% industry), supported by historical revenue growth of 42.6%. Valuation shows PEG of 0.79 indicating undervaluation despite premium PE of 39.1x. Financial health shows moderate concern with debt-to-equity of 1.58 (vs 1.27 industry) but strong cash position of $7.27 billion and free cash flow of $1.95 billion provide adequate cushion. Additional metrics: PE Ratio: 39.13
News Sentiment
Eli Lilly is making bold strategic moves to cement its position as the leader in the booming obesity treatment market while expanding its oncology footprint. The pharmaceutical giant has been on an acquisition spree, announcing deals to purchase Kelonia Therapeutics for $3.25 billion and Ajax Therapeutics for up to $2.3 billion, signaling confidence in its growth strategy. The company's newly launched obesity pill Foundayo is showing promising early traction with nearly 4,000 prescriptions in just its second week, though it's facing stiff competition from Novo Nordisk's oral Wegovy in early market uptake. These developments come as Lilly continues to capitalize on the massive obesity treatment opportunity, with analysts projecting significant revenue potential from this expanding market. The acquisitions, particularly Kelonia's blood cancer therapies, demonstrate Lilly's commitment to diversifying beyond its diabetes and obesity franchise while building next-generation treatment capabilities. For investors, these moves represent Lilly's aggressive pursuit of growth opportunities in high-value therapeutic areas, though execution will be critical to justify the company's premium valuation and ambitious growth targets.
Risk Assessment
Primary risks include execution on obesity drug market penetration, integration of recent acquisitions, and maintaining growth rates to justify premium valuation. Debt-to-equity of 1.58 requires monitoring but strong cash flows of $1.95B provide adequate coverage. Competitive pressure in diabetes/obesity space from Novo Nordisk requires continued innovation. Mitigation through diversified pipeline, strong balance sheet, and proven execution track record.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is LLY a halal stock?
Yes, Eli Lilly and Company (LLY) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for LLY?
Eli Lilly and Company (LLY) has a Plutrex AI rating of 88.5/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is LLY a good investment?
According to Plutrex AI, LLY has a Strong Buy rating (88.5/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in LLY?
US stocks like LLY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in LLY?
Plutrex AI identifies the main risks for LLY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.